The total volume of pharmacy sales of medicines and dietary supplements of the Russian pharmaceutical company Binnopharm Group in 2024 exceeded 48 billion rubles, the press service of the company reported. The sales distribution between drugs and dietary supplements was 93.5% for drugs and 6.5% for dietary supplements.
The Binnopharm Group took the sixth place among the leaders of the pharmaceutical market, the company added, citing the data of the analytical agency AlphaRM. Retail sales increased by 19% compared to 2023. By the end of 2024, it became the second largest manufacturer among Russian pharmaceutical companies in the retail market with a share of 2.7%. The company’s growth has been driven by a balanced and diversified portfolio of medicines in different categories.
«We continue to be proactive in developing our portfolio, investing in innovation and working closely with the medical community, pharmacy chains and distributors. This allows us to confidently move forward by offering high–quality and in-demand drugs to the market», — said Ekaterina Slavgorodskaya, Director of Sales and Promotion at Binnopharm Group.
The Binnopharm Group also follows the strategy of expanding its portfolio in the markets of the near and far abroad, transferring successful solutions to new territories. Previously, the company announced that it has submitted an application for registration of its flagship product, Neobutin, in China. Neobutin currently has effective registration certificates in Azerbaijan, Armenia, Belarus, Georgia, Kyrgyzstan, Moldova, and Uzbekistan.
